$2 Billion is the total value of NEA Management Company, LLC's 57 reported holdings in Q3 2022. The portfolio turnover from Q2 2022 to Q3 2022 was 17.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| BHG | BRIGHT HEALTH GROUP INC | $229,123,000 | -42.3% | 218,212,126 | 0.0% | 11.44% | -43.9% | |
| COUR | COURSERA INC | $171,055,000 | -24.0% | 15,867,769 | 0.0% | 8.54% | -26.1% | |
| IONQ INC | $133,595,000 | +15.8% | 26,350,067 | 0.0% | 6.67% | +12.5% | ||
| ARCELLX INC | $126,702,000 | +12.4% | 6,750,264 | 0.0% | 6.32% | +9.3% | ||
| RYTM | RHYTHM PHARMACEUTICALS INC | $108,316,000 | +431.3% | 4,912,306 | 0.0% | 5.41% | +416.4% | |
| CRSP | CRISPR THERAPEUTICS AGnamen akt | $103,907,000 | +7.5% | 1,590,002 | 0.0% | 5.19% | +4.5% | |
| NET | CLOUDFLARE INC | $103,845,000 | +26.4% | 1,877,510 | 0.0% | 5.18% | +22.8% | |
| New | ZEROFOX HLDGS INC | $88,283,000 | – | 18,090,861 | +100.0% | 4.41% | – | |
| MIRM | MIRUM PHARMACEUTICALS INC | $87,986,000 | +8.0% | 4,187,801 | 0.0% | 4.39% | +4.9% | |
| BERKSHIRE GREY INC | $64,985,000 | +17.2% | 38,226,621 | 0.0% | 3.24% | +13.9% | ||
| GLUE | MONTE ROSA THERAPEUTICS INC | $62,935,000 | -15.5% | 7,703,205 | 0.0% | 3.14% | -17.9% | |
| VRNA | Buy | VERONA PHARMA PLCads | $57,076,000 | +166.6% | 5,584,753 | +9.3% | 2.85% | +159.2% |
| NKTX | NKARTA INC | $47,003,000 | +6.8% | 3,571,640 | 0.0% | 2.35% | +3.8% | |
| GOSS | New | GOSSAMER BIO INC | $41,540,000 | – | 3,467,406 | +100.0% | 2.07% | – |
| GERN | GERON CORP | $38,186,000 | +51.0% | 16,318,681 | 0.0% | 1.91% | +46.7% | |
| SVRA | SAVARA INC | $37,414,000 | +2.0% | 24,137,931 | 0.0% | 1.87% | -0.9% | |
| DM | DESKTOP METAL INC | $37,316,000 | +17.7% | 14,407,594 | 0.0% | 1.86% | +14.4% | |
| ALLK | Buy | ALLAKOS INC | $33,867,000 | +399.8% | 6,148,704 | +184.0% | 1.69% | +385.6% |
| OYST | OYSTER PT PHARMA INC | $33,300,000 | +29.8% | 5,925,287 | 0.0% | 1.66% | +26.1% | |
| AVEO | AVEO PHARMACEUTICALS INC | $32,533,000 | +25.5% | 3,952,957 | 0.0% | 1.62% | +21.9% | |
| AUPH | AURINIA PHARMACEUTICALS INC | $29,853,000 | -25.2% | 3,969,834 | 0.0% | 1.49% | -27.3% | |
| AKUS | AKOUOS INC | $29,058,000 | +44.1% | 4,298,488 | 0.0% | 1.45% | +40.1% | |
| BUZZFEED INC | $23,921,000 | +1.3% | 15,333,892 | 0.0% | 1.19% | -1.6% | ||
| CVRX | CVRX INC | $22,120,000 | +55.2% | 2,370,858 | 0.0% | 1.10% | +50.8% | |
| NEXTNAV INC | $22,029,000 | +18.5% | 8,189,156 | 0.0% | 1.10% | +15.2% | ||
| CTIC | Sell | CTI BIOPHARMA CORP | $21,451,000 | -55.3% | 3,685,683 | -54.2% | 1.07% | -56.6% |
| IVA | INVENTIVA SAads | $19,907,000 | -37.0% | 5,572,953 | 0.0% | 0.99% | -38.8% | |
| STSA | SATSUMA PHARMACEUTICALS INC | $18,858,000 | +44.9% | 3,142,958 | 0.0% | 0.94% | +40.9% | |
| ADAP | ADAPTIMMUNE THERAPEUTICS PLCsponds adr | $18,364,000 | -36.8% | 17,082,612 | 0.0% | 0.92% | -38.5% | |
| TRVI | TREVI THERAPEUTICS INC | $17,515,000 | -45.2% | 11,373,174 | 0.0% | 0.87% | -46.7% | |
| RPHM | RENEO PHARMACEUTICALS INC | $16,036,000 | +26.4% | 4,786,921 | 0.0% | 0.80% | +22.7% | |
| CSBR | CHAMPIONS ONCOLOGY INC | $12,853,000 | -6.3% | 1,713,720 | 0.0% | 0.64% | -8.8% | |
| XFOR | New | X4 PHARMACEUTICALS INC | $11,155,000 | – | 6,523,157 | +100.0% | 0.56% | – |
| AFMD | AFFIMED NV | $9,119,000 | -25.6% | 4,426,488 | 0.0% | 0.46% | -27.8% | |
| New | FISCALNOTE HOLDINGS INC | $8,634,000 | – | 1,694,323 | +100.0% | 0.43% | – | |
| BILL | BILL COM HLDGS INC | $8,312,000 | +20.4% | 66,100 | 0.0% | 0.42% | +16.9% | |
| SENTI BIOSCIENCES INC | $8,233,000 | +10.4% | 4,429,725 | 0.0% | 0.41% | +7.3% | ||
| MINERVA SURGICAL INC | $7,956,000 | -66.2% | 10,001,937 | 0.0% | 0.40% | -67.1% | ||
| INZY | INOZYME PHARMA INC | $6,551,000 | -37.6% | 2,444,379 | 0.0% | 0.33% | -39.3% | |
| BDTX | BLACK DIAMOND THERAPEUTICS INC | $5,830,000 | -31.3% | 3,449,845 | 0.0% | 0.29% | -33.3% | |
| LXRX | LEXICON PHARMACEUTICALS INC | $5,717,000 | +29.0% | 2,382,286 | 0.0% | 0.28% | +25.0% | |
| XERIS BIOPHARMA HOLDINGS INC | $5,065,000 | +1.3% | 3,246,785 | 0.0% | 0.25% | -1.6% | ||
| GLYC | GLYCOMIMETICS INC | $5,014,000 | -7.7% | 9,089,041 | 0.0% | 0.25% | -10.4% | |
| EAR | EARGO INC | $4,747,000 | +39.7% | 4,520,849 | 0.0% | 0.24% | +35.4% | |
| TUYA | New | TUYA INCsponsered ads | $4,588,000 | – | 4,934,640 | +100.0% | 0.23% | – |
| SYBX | SYNLOGIC INC | $4,018,000 | -17.4% | 4,229,410 | 0.0% | 0.20% | -19.6% | |
| MRKR | MARKER THERAPEUTICS INC | $3,951,000 | +11.7% | 10,714,285 | 0.0% | 0.20% | +8.2% | |
| MEIP | MEI PHARMA INC | $3,299,000 | -36.1% | 8,533,072 | 0.0% | 0.16% | -37.7% | |
| AIRSPAN NETWORKS HOLDINGS INC | $3,100,000 | -32.4% | 1,534,633 | 0.0% | 0.16% | -34.3% | ||
| RGLS | REGULUS THERAPEUTICS INC | $2,457,000 | -17.9% | 1,445,115 | 0.0% | 0.12% | -20.1% | |
| UP | WHEELS UP EXPERIENCE INC | $1,220,000 | -41.0% | 1,061,259 | 0.0% | 0.06% | -42.5% | |
| PHAS | PHASEBIO PHARMACEUTICALS INC | $1,169,000 | -70.7% | 6,643,702 | 0.0% | 0.06% | -71.7% | |
| ADXN | Buy | ADDEX THERAPEUTICS LTDsponsored ads | $830,000 | -23.4% | 5,648,690 | +500.0% | 0.04% | -26.8% |
| OBSV | OBSEVA SA | $652,000 | -91.2% | 4,586,563 | 0.0% | 0.03% | -91.3% | |
| TCON | TRACON PHARMACEUTICALS INC | $579,000 | -16.5% | 346,719 | 0.0% | 0.03% | -19.4% | |
| AKTX | AKARI THERAPEUTICS PLCsponsored adr | $285,000 | -36.9% | 452,167 | 0.0% | 0.01% | -39.1% | |
| PANW | Sell | PALO ALTO NETWORKS INC | $22,000 | -99.9% | 141 | -99.6% | 0.00% | -99.9% |
| LUMO | Exit | LUMOS PHARMA INC | $0 | – | -65,374 | -100.0% | -0.03% | – |
| IMRA | Exit | IMARA INC | $0 | – | -1,006,722 | -100.0% | -0.06% | – |
| GLBE | Exit | GLOBAL E ONLINE LTD | $0 | – | -436,282 | -100.0% | -0.41% | – |
| MILE | Exit | METROMILE INC | $0 | – | -9,384,285 | -100.0% | -0.44% | – |
| VTGN | Exit | VISTAGEN THERAPEUTICS INC | $0 | – | -16,302,596 | -100.0% | -0.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| GLYCOMIMETICS INC | 39 | Q3 2023 | 7.6% |
| AURINIA PHARMACEUTICALS INC | 37 | Q3 2023 | 5.0% |
| CHAMPIONS ONCOLOGY INC | 33 | Q3 2023 | 1.2% |
| LEXICON PHARMACEUTICALS INC | 32 | Q3 2023 | 2.0% |
| ADAPTIMMUNE THERAPEUTICS PLC | 31 | Q3 2023 | 9.3% |
| TREVENA INC | 31 | Q3 2021 | 3.3% |
| AKARI THERAPEUTICS PLC | 31 | Q2 2023 | 0.3% |
| ARDELYX INC | 29 | Q3 2021 | 11.9% |
| RIGEL PHARMACEUTICALS INC | 29 | Q2 2020 | 0.6% |
| EPIZYME INC | 28 | Q1 2020 | 9.6% |
View NEA Management Company, LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-11 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-10 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
| 13F-HR | 2022-05-16 |
| 13F-HR | 2022-02-14 |
| 13F-HR | 2021-11-12 |
View NEA Management Company, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.